This year’s annual meeting of the Society for Melanoma Research (SMR) will take place from November 20-23 in Salt Lake City, UT. Once again, SMR has designated a special session of the Congress specifically to rare melanomas. Dr. Kasey Couts will be presenting her research on mucosal melanoma immune responses in this session. Other research personnel, including Robert Van Gulick and Morgan MacBeth, will be presenting posters on their research involving rare melanomas including a summary of the biorepository’s rare melanoma models and the identification of a new BRAF gene splice variant in ocular melanoma. You can follow highlights from this year’s meeting on SMR’s twitter account (@SocietyMelanoma).
When you think of melanoma, you picture the sun. But there is another rare class of these dangerous melanomas that has nothing to do with sun exposure. Building on a unique expertise developed while researching and treating Colorado’s mile-high rate of sun-associated melanoma, University of Colorado Cancer Center recently earned designation as a Center for Rare Melanomas. The Center was established from a $1.5M award from the Patten Davis Foundation, and will help the team capture data from their clinical efforts that will aid in creating new understanding of, and new treatments, for the condition.
The Society for Melanoma Research (SMR) hosts an annual International Congress where researchers from around the world share their cutting edge work in melanoma. For the first time this year, the Congress has designated a special session focused specifically on rare melanomas. Dr. Kasey Couts is one of five speakers invited to share her research during this inaugural session. She will present the results of a collaboration with Foundation Medicine, Inc., a clinical testing company, which analyzed the genomics of rare melanomas and identified new targeted therapies that are effective in rare melanoma pre-clinical models and patients.
A University of Colorado Cancer Center study published in the journal Molecular Cancer Therapeutics may offer hope to some of patients with melanomas caused by genetic changes not related to sun exposure. The study finds a genetic change called ALK-fusion in a patient sample of a melanoma subtype called mucosal melanoma. When researchers treated a tumor grown from this sample with the drugs crizotinib and ceritinib – both FDA approved to treat ALK-positive lung cancer – the tumor responded dramatically.
This year’s International Pigment Cell Conference (IPCC) is being held in Denver, CO, from August 26-30. Topics at the annual IPCC meetings cover a wide variety of skin-related research topics, including basic skin cell functions, skin disorders, and cancers of the skin including melanoma. Two researchers from the CU Anschutz Medical Campus, Dr. Kasey Couts and Dr. Jennifer Hintzsche, will be presenting their research on rare, non-sun exposed melanomas.
While most melanomas appear on the skin as the result of sun exposure, a small subset of melanomas arise spontaneously from mucosal tissues. A University of Colorado Cancer Center study published in the journal Melanoma Research demonstrates novel mutations involved in mucosal melanoma, paving the way for therapies to treat this overlooked subtype.